RESEARCH SHOWS THAT PLANTS CURE CANCER, NOT CHEMICALS!
I found good research material which sounds probable Copernican revolution which has already been taken place in cancer theory. Right now, today great weight with evidence shows that plants and not chemicals are the solution for reversing the global cancer epidemic.
Personally, even as a child when went to bible study, we learned that many things which God created is for healing purposes for our bodies and mind. The question is, why does man refute this?
The very beginning of the bible in Genesis 9:3 “Every moving thing that lives shall be food for you. And as I gave you the green plants, I give you everything.”
There are 68 verses in the bible which speak on herbs for healing and 22 verses which speak on herbs and plants for healing our body.
I do realize that there are verses in the bible to be refuted, but when something is true and you know from actually doing yourself to get off of all prescribed medications, how is it not true?
There are many proven cases on the internet and have met many many who have testimonies of actual healing of diseases which many say are not curable.
Many cases such as Dr. Terry Wahl’s who cured and healed her mitrochondria and beat MS is big proof that what needs addressing our body’s healing is the mitrochondria.
It is being proven in many cases that nutrition is a cure for many disease and illness.
Why do doctors believe that by killing is an alternative to actually curing and healing?
When do many doctors propose to have success stories to share and give HOPE to many instead thinking they are God and predicting death dates or months we have to live?
Of course, when you give chemo doesn’t this harm the patient even more and why do you think something has to make us sicker to heal us? I will never understand this and isn’t this theory and hogwash?
I will never believe man’s word nor cures are for healing our bodies, soul or minds and only God is the healer.
God’s healing is not theory, man’s cures are!
Just imagine not long from now when the customary restorative foundation unreservedly recognizes that growth is a characteristic reaction to many years of culminative exposures to unnatural, developmentally phenomenal substance, electromagnetic, psychospiritual exposures and conditions. Rather than attacking and viciously smothering the indication of this impeccable tempest of danger – malignancy – illuminated professionals will figure out how to address, evacuate and review the underlying drivers, concentrating on recreating the conditions that backing our hereditary and epigenetic outline of wellbeing and health.
It is the objective of GreenMedInfo.com to give the general population and expert populaces an asset to influence the developing confirmation to do precisely that. The accompanying database segments are intended to make this assignment less demanding:
As far as understanding both how cancer is caused and how it can be effectively treated.
Thanks in large part to the discovery that it is an exemplar of epigenetic dysfunction and not a predestined byproduct of dysfunctional genetic information inherited from distant ancestors.
GENOMES AND DECODING CANCER PATIENTS
Two new studies highlight the force of sequencing tumor patients’ genomes as an indicative device, offering specialists some assistance with deciding the best course of treatment and scientists recognize new growth vulnerability transformations that can be gone from guardian to youngster.
Both studies, by specialists at Washington University School of Medicine in St. Louis, are accounted for April 20 in the Journal of the American Medical Association.
In one case, sequencing the genome of a 39-year-old lady with intense myeloid leukemia (AML) revealed a novel hereditary oversight, driving specialists to change the course of her treatment. Rather than an undifferentiated cell transplant, which had been suggested in light of the fact that standard testing showed poor survival chances, she was treated with a focused on chemotherapy regimen and is currently going away.
In another, sequencing the genome of a lady who passed on at age 42 in the wake of creating bosom and ovarian growth and afterward leukemia permitted specialists to distinguish another change in a quality known not expand disease hazard. The patient’s relatives were educated of the finding, and hereditary advising and testing were prescribed for the lady’s three kids, who have a high danger of creating disease at a youthful age on the off chance that they acquired the change.
PERSONALIZED GENOMIC MEDICINE
“These instances of customized genomic prescription are only a percentage of the main cases of what will probably be typical sooner rather than later,” compose Boris Pasche, MD, PhD, of the University of Alabama in Birmingham, and Devin Absher, PhD, of the HudsonAlpha Institute for Biotechnology in Alabama, in a publication that goes with the papers.
“We are starting to perceive how genome sequencing can have a genuine effect in the lives of malignancy patients and their families,” says senior creator Richard K. Wilson, PhD, executive of Washington University’s Genome Institute and a pioneer in the field of disease genome sequencing. “Both studies underscore the estimation of entire genome sequencing as an analytic instrument. We couldn’t have distinguished these transformations utilizing routine tests or focused on sequencing approaches in light of the fact that they included sudden auxiliary changes to the DNA, which must be found by looking over the whole genome.”
Progresses in innovation have empowered researchers to grouping the genomes of tumor patients at an expense and speed that was incredible even a couple of years back.
In any case, Wilson alerts that it’s not yet handy to routinely succession disease patients’ genomes in light of the fact that the expense is still moderately high, and researchers don’t yet completely comprehend the broadness of hereditary changes that drive malignancy advancement. Select cases like these, be that as it may, offer a look at the way customized genome sequencing can change the way specialists analyze and treat growth patients and their families.
In the primary study, the patient was alluded to the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine for an undeveloped cell transplant. Be that as it may, specialists immediately understood her case was a demonstrative problem. From one viewpoint, numerous components of her leukemia cells demonstrated a great instance of intense promyelocytic leukemia (APL), a subtype of AML.
However, the patient did not have a typical hereditary modification connected with APL: a bit of chromosome 15 that is swapped with a bit of chromosome 17, which would have given a conclusive determination. This deformity makes a combination of two qualities that keeps white platelets from developing, and it is known not APL.
Patients who have the 15;17 chromosome swap needn’t bother with a foundational microorganism transplant since they can be adequately treated with a chemotherapy regimen that incorporates all-trans retinoic corrosive, or ATRA, which focuses on the hereditary blunder.
The foundational microorganism transplant had been prescribed for this patient on the grounds that a standard demonstrative test showed her chances of long haul survival were under 15 percent. The test demonstrated that various chromosomes in her leukemia cells were absent, broken or reworked, which is connected with an exceptionally poor anticipation.
The patient’s oncologist, Peter Westervelt, MD, PhD, chief of the Bone Marrow Transplant/Leukemia Section in the Division of Oncology at Washington University, proposed that sequencing her genome could resolve the analytic difficulty.
“We would not like to proceed with an undifferentiated cell transplant unless we were totally sure she required it,” he says. “It’s an extremely thorough treatment, with a critical danger of mortality and long haul entanglements. Sequencing the genome of the patient’s leukemia cells offered the chance to determine this quandary ‘continuously’ and permitted us to make the right bring in suggesting further treatment.”
The analysts sequenced both the genome of the patient’s malignancy cells and the genome of her typical, sound cells, taken from a skin test. By contrasting the DNA groupings one next to the other, they could recognize changes in the leukemia cells that added to her disease.
Not at all like sequencing procedures that attention just on qualities, which make up only 1 percent of the genome, entire genome sequencing catches the full scope of hereditary modifications in DNA, including both little and huge insertions, cancellations and other basic varieties.
“Entire genome sequencing is the most intense analytic device we’ve ever needed to characterize every one of the transformations in the genome of a malignancy persistent,” says co-creator Timothy Ley, MD, partner chief of The Genome Institute and the Lewis T. also, Rosalind B. Apple Professor of Oncology at Washington University. “We no more need to depend on procedures where we’re think about what could not be right. Presently, we can discover all the hereditary changes that added to a patient’s growth. As we advance, we think this will prompt more chances to enhance the consideration of patients and their families.”
Wilson, Mardis and Ley and their associates have spearheaded entire genome sequencing of tumor patients’ DNA to distinguish hereditary changes at the base of the infection. To date, they have sequenced the genomes of more than 300 disease patients and their tumors.